Al Hammadi Holding · TADAWUL:4007
Al Hammadi — 9M 2023 Earnings Presentation
20 slides from Al Hammadi's earnings presentation, November 2023
Slide 1: Investor Presentation 9M 2023
Al Hammadi Holding Investor Presentation 9M 2023
Slide 2: Table of Contents
Table of Contents I II III About Al Hammadi Holding 9M 2023 Appendix Results Overview
Slide 3: About Al Hammadi Holding
About Al Hammadi Holding
Slide 4: Al Hammadi is an integrated healthcare company and premier hospital operator
Al Hammadi is an integrated healthcare company and premier hospital operator providing world-class healthcare services to hundreds of thousands of local and foreign residents… An Integrated Healthcare Company 80%1 20%1 The company currently operates two hospitals in the Saudi Arabian capital, housin
Slide 5: Riyadh coverage across the Saudi capital
The Company enjoys widespread coverage spanning the entire Saudi capital Al Narjis Hospital2 4 Al Nuzha Hospital 3 Al Hammadi boasts two operational state-of-the-art facilities, Al Nuzha and Al Suwaidi hospitals, strategically located in the heart Riyadh Olaya Hospital1 of Riyadh, with a third hospi
Slide 6: Al Hammadi operates two premier hospitals in the heart of Riyadh
Al Hammadi operates two premier hospitals in the heart of Riyadh providing a wide range of world-class services to thousands of patients Patient Class Mix Patient Class Mix Al Nuzha Hospital 2022 Al Suwaidi Hospital 2022 Located in the northeast neighborhood of Launched in 2015 and located in southw
Slide 7: Growth plans to add rooms and 240 clinics by 2028
The Group’s ambitious growth plans will see it add 400 rooms and 240 clinics by 2028 to capitalize on the city’s growing healthcare demand Al Suwaidi Hospital Olaya Hospital Al Narjis Hospital Al Hammadi is looking to Originally launched in 1985, The Group plans to open its leverage Al Suwaidi’s spa
Slide 8: 9M 2023 Results Overview
9M 2023 Results Overview
Slide 9: 9M 2023 Results Snapshot
9M 2023 Results Snapshot Al Hammadi carried the momentum forward from the first half of the year to deliver strong results in 9M 2023. Revenue Gross Profit Operating Profit Net Profit SAR 873 Million SAR 325 Million SAR 272 Million SAR 238 Million 9M 2023 (▲12.0% y-o-y) 9M 2023 (▲12.7% y-o-y) 9M 202
Slide 10: 9M 2023 Operational Review
9M 2023 Operational Review Inpatient volumes slightly declined in the first nine months of 2023 compared to 9M 2022, while outpatient examination marginally increased versus the comparable period of 2022. Inpatient Admissions | ‘000 Outpatient Examinations| ‘000 ▲11% ▲6% ▲ 1% ▼7% 45.0 1,038.6 40.2 9
Slide 11: Consolidated Financial Performance (I/III)
9M 2023 Consolidated Financial Performance (I/III) Top-line growth for the nine-month period was supported by strong revenues across Al Hammadi’s medical services and pharmaceutical segments during the period. Revenues maintain growth trend, with insurance proportion of overall revenues increasing A
Slide 12: Consolidated Financial Performance (II/III)
9M 2023 Consolidated Financial Performance (II/III) Strong profitability was primarily driven by robust top-line growth filtering down to the bottom-line, coupled with improved cost efficiencies. Cost optimization measures successfully maintaining general and operating expenses as a share of revenue
Slide 13: Consolidated Financial Performance (III/III)
9M 2023 Consolidated Financial Performance (III/III) Strong net profit on the back of higher revenues and solid operating profits over the nine-month period. Net Profit before Zakat | SAR Mn Net Profit | SAR Mn 27.3% 350 25.5% 23.6% 24.4% 29.0% 30.0% 22.9% 300 15.2% 11.4% 20.0% ▲ 27.1% 13.0% 250 10.
Slide 14: Al Nuzha Hospital: 9M 2023 Performance
Al Nuzha Hospital: 9M 2023 Performance Continued top-line growth reported despite lower patient volumes in 9M 2023. Patient volumes slightly affected due to slowdown during Eid and summer holidays Outpatient Examinations | ‘000 Inpatient Admissions | ‘000 41.0% CAGR 47.9% CAGR 642.6 26.0 520.7 21.0
Slide 15: Al Suwaidi Hospital: 9M 2023 Performance
Al Suwaidi Hospital: 9M 2023 Performance Al- Suwaidi’s top-line grew on the back of higher outpatient volumes in 9M 2023. Patient volumes to return to year-on-year growth in 2H 2023 as traffic normalizes post Eid vacation Outpatient Examinations | ‘000 Inpatient Admissions | ‘000 5.8% CAGR 10.3% CAG
Slide 16: Pharmaceuticals: 9M 2023 Performance Review
Pharmaceuticals: 9M 2023 Performance Review Al Hammadi’s pharmaceutical sales contributed 20% of consolidated revenues, recording SAR 174 million for 9M 2023. This represent a 16% y-o-y rise supported by both increased in-house and Pharma Serve sales. Revenue from In-House Pharmacies| SAR Mn Revenue
Slide 17: Appendix
Appendix
Slide 18: Consolidated Income Statement
9M 2023 Consolidated Income Statement SAR mn Q3 2022 Q3 2023 Y-o-Y Change 9M 2022 9M 2023 Y-o-Y Change Revenue 246.9 297.8 20.6% 779.8 873.1 12.0% Cost of revenue (163.4) (185.0) 13.2% (491.1) (547.7) 11.5% Gross Profit 83.5 112.9 35.2% 288.7 325.4 12.7% GPM 33.8% 37.9% 4.1pts 37.0% 37.3% 0.3pts Sel
Slide 19: Consolidated Balance Sheet
9M 2023 Consolidated Balance Sheet SAR mn 31 December 2022 30 September 2023 ASSETS Non-current assets Property and equipment 1,606.2 1,674.4 Advance payments for acquisition of property and equipment 95.8 - Intangible assets and goodwill 28.5 25.9 Investment in associates 124.2 125.4 Total non-curr
Slide 20: Consolidated Statement of Cash Flow
9M 2023 Consolidated Statement of Cash Flow SAR mn 30 Sep 2022 30 Sep 2023 OPERATING ACTIVITIES Net profit 184.2 238.1 Adjustments to reconcile net profit to cash flow - - Depreciation of property and equipment and right of use assets 74.3 72.7 Amortization of intangible assets 2.8 2.7 Losses on dis